Amgen announced successful late-stage trials for two antibody drugs targeting immune-mediated diseases, but they did not clearly outperform existing competitors. In trials for eczema and myasthenia gravis, the drug rocatinlimab showed effectiveness in reducing skin lesions and overall disease severity. It outperformed a placebo in reducing outbreaks of red, itchy lesions, with 32.8% of patients seeing improvement compared to 13.7% on placebo. The drug was also effective in reducing overall disease severity as assessed by doctors. Amgen reported that the treatment was generally safe and well-tolerated.
Source link
Amgen reports success for eczema and myasthenia gravis treatments
